Survodutide
Fat LossInvestigational GLP-1/glucagon agonistEmerging
Boehringer Ingelheim / Zealand GLP-1/glucagon dual agonist in Phase 3 for obesity and MASH. Not FDA-approved.
For research use only.
Key Facts
- CAS
- 2805997-46-8
- Molecular Weight (MW)
- ≈4232 g/mol
- Half-life
- ~6 days (once-weekly)
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Weekly
- Last updated
- 8/23/2026
- Targets
- GLP-1 receptorGlucagon receptor
Overview
Boehringer Ingelheim / Zealand GLP-1/glucagon dual agonist in Phase 3 for obesity and MASH. Not FDA-approved.
Protocol
- Dosage Range
- Investigational - dosage under evaluation in clinical trials
- Frequency
- Weekly
- Cycle
- Per study
- Administration Route
- Subcutaneous
- Reconstitution Guide
- Investigational - not yet established
Science
Mechanism of Action
Dual GCGR/GLP-1R agonism for appetite reduction plus hepatic energy expenditure; Phase 2 showed substantial weight loss and MASH histologic signals.
Targets
GLP-1 receptorGlucagon receptor
Studies
- Survodutide phase 2 obesity— Journal/year not available
Benefits
Obesity/MASH research candidate
Potential Side Effects
- GI AEs
- Increased heart rate
References
- PMID 37932132External link · Year —